

Ellen W. Collisson, et al.
Serial No.: Not Yet Known
Filed: Herewith

- 09303510-003009
- 51. (New) The oligonucleotide of claim 50, wherein the detectable label comprises a radioisotope, a fluorophor, or biotin.
- 52. (New) The oligonucleotide of claim 48, wherein the oligonucleotide is selectively methylated.
- 53. (New) A vector comprising the nucleic acid of claim 1.
- 54. (New) The plasmid vector of claim 53 designated PSI-B7-1/871-35 (ATCC Accession No. 209817).
- 55. (New) A vector comprising the nucleic acid of claim 2.
- 56. (New) The plasmid vector of claim 55 designated B7-2#19-2/011298 (ATCC Accession No. 209821).
- 57. (New) A vector comprising the nucleic acid of claim 3.
- 58. (New) The plasmid vector of claim 57 designated PSI-CD28 #7/100296 (ATCC Accession No. 209819).
- 59. (New) A vector comprising the nucleic acid of claim 4.
- 60. (New) The plasmid vector of claim 59 designated CTLA-4# 1/091997 (ATCC Accession No. 209820).
- 61. (New) The vector of claim 53, comprising a promoter operably linked to the nucleic acid.
- 62. (New) A host cell which comprises a vector of ~~any of~~ claim 53.
- 63. (New) The host cell of claim 62, wherein the host cell is a eukaryotic or a prokaryotic cell.

Ellen W. Collisson, et al.
Serial No.: Not Yet Known
Filed: Herewith

- B
- 64. 8 (New) The host cell of claim ~~63~~⁷, wherein the host cell is selected from the group consisting of: E. coli, yeast, COS cells, PC12 cells, CHO cells, and GH4C1 cells.
- 65. (New) A polypeptide encoded by the nucleic acid of claim 1.
- 66. (New) A polypeptide encoded by the nucleic acid of claim 2.
- 67. (New) A polypeptide encoded by the nucleic acid of claim 3.
- 68. (New) A polypeptide encoded by the nucleic acid of claim 4.
- 69. (New) A method of producing the polypeptide of claim 65 which comprising culturing a host cell which expresses the polypeptide and recovering the polypeptide so produced.
- 70. (New) A vaccine comprising an effective amount of a polypeptide of any of claim 65 and a suitable carrier.
- 71. (New) A vaccine of claim 70, wherein the effective amount is an amount from about 0.01 mg to about 100mg per dose.
- 72. (New) A vaccine of claim 70, wherein the effective amount is an amount from about 0.25 mg/kg weight body of a feline /day to about 25 mg/kg weight of a feline/day.
- 73. (New) A vaccine of claim 70 which further comprises an immunogen derived from a pathogen.
- 66040.07500000
- R

Ellen W. Collisson, et al.
Serial No.: Not Yet Known
Filed: Herewith

- 660240 OF 520000
- 74. (New) A vaccine of claims 73, wherein the pathogen in a feline pathogen a rabies virus, Chlamydia, Toxoplasmosis gondii, Dirofilaria immitis, a flea, or a bacterial pathogen.
- 75. (New) A vaccine of claim 74 wherein the feline pathogen is feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), feline infectious peritonitis virus (FIP), feline panleukopenia virus, feline calicivirus, feline reovirus type 3, feline rotavirus, feline coronavirus, feline syncytial virus, feline sarcoma virus, feline herpesvirus, feline Born disease virus, or a feline parasite.
- 76. (New) A method of inducing immunity in a feline which comprises administering to the feline a dose of a vaccine of any of claim 73.
- 77. (New) A method of enhancing an immune response in a feline which comprises administering to the feline a dose of a vaccine of any of claim 73.
- 78. (New) The method of claim 76 wherein the vaccine is administered subcutaneously, intramuscularly, systemically, topically, or orally.
- 79. (New) A method for suppressing an immune response in a feline which comprises administering to the feline an effective immune response suppressing amount of a polypeptide of claim 68.
- 80. (New) A method for suppressing an immune response in a feline which comprises administering to the feline an effective immune response suppressing amount of a soluble polypeptide of claim 65.
- R